CuraSen Therapeutics announced that it has dosed its first subjects in a multi-part, Phase 1 clinical study with CST-2032, the company’s first proprietary compound intended for the treatment of neurodegenerative disease.
Melior Pharmaceuticals has been awarded a grant from the Commonwealth of Pennsylvania’s COVID-19 Vaccines, Treatments and Therapies (CV-VTT) Program, which is designed to support rapid advancement of promising COVID-19 therapies.
Daiichi Sankyo Company announced that the first patient has been dosed in a phase 2 study evaluating patritumab deruxtecan (U3-1402), a HER3 directed DXd antibody drug conjugate (ADC), in patients with advanced or metastatic colorectal cancer who are resistant, refractory, or intolerant to at least two prior lines of systemic therapy.
Eli Lilly and Company and Incyte announced initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Pfizer and BioNTech announced that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.
Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
Axon Neuroscience announced that its ACvac1 peptide vaccine has demonstrated significant effect against the SARS CoV-2 virus in the pre-clinical study.
AstraZeneca has temporarily stopped worldwide trials of its investigational AZD1222 vaccine for Covid-19 following an unexplained event of a participant falling sick.
Bayer said that the phase 4 REPLACE trial evaluating Adempas (riociguat) in intermediate-risk adult patients with pulmonary arterial hypertension (PAH) has met its primary endpoint.
Novartis announced that high-dose, once-daily Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) significantly reduces both moderate-or-severe and severe asthma exacerbation rates in patients whose asthma is uncontrolled on medium- or high-dose long-acting beta2-agonist (LABA)/inhaled corticosteroids (ICS), when compared with a once-daily medium-dose of the same treatment.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.